Digital Mind Body Intervention Among Black and Hispanic Patients Living With Inflammatory Bowel Disease

The 8-item Brief Illness Perception Questionnaire (BIPQ) will be used to assess self-reported Illness Perception. Responses to the eight questions related are scored from 0 (negligible illness impact) to 10 (intense illness impact) for a possible scoring range of 0-80. Higher scores indicate more severe patient perception of illness impact. Group mean scores will be summarized.

IBD self-efficacy will be evaluated based on the 13-item IBD Self Efficacy Scale (IBD-SES) which measure the composite score across four domains of self-efficacy (managing stress and emotions, medical care, symptoms and disease, and maintaining remission). Responses to the 13 questions are scored from 0 (Not sure at all) to 10 (Totally sure) for a possible scoring range of 0-130. Higher scores are associated with increased patient self-efficacy across the four domains. Group mean scores will be summarized.

Patient disease acceptance will be assessed using the 20-item Digestive Disease Acceptance Questionnaire (DDAQ). The DDAQ consists of 20 statements asking patients to rate the truth of each statement on a scale ranging from 0 (Never True) to 6 (Always True) for an overall possible scoring range of 0-120. Higher scores are associated with increased patient disease acceptance. Group mean scores will be summarized.

Mindfulness is evaluated based on the 15-item Five Facet Mindfulness Questionnaire (FFMQ-15). The FFMQ measures mindfulness with regards to thoughts, experiences, and actions in daily life across five subscales. Responses to the positively worded statements (Statements 1-2, 5-6, 10-12, 15) are scored from 1 (Never or very rarely true) to 5 (Very often or always true). Responses to the negatively worded statements (Statements 3-4, 7-9, 13-14) are scored from 5 (Never or very rarely true) to 1 (Very often or always true) for an overall possible scoring range of 15-75. Higher scores are indicative of someone who is more mindful in their everyday life. Group mean scores will be summarized.

GI-specific symptom anxiety will be based on responses to the 15-item Visceral Sensitivity Index (VSI) questionnaire. The VSI consists of 15 statements describing how people respond to abdominal symptoms/discomfort. Individual responses are scored on a scale ranging from 1 (Strongly Disagree) to 6 (Strongly Agree) yielding a range of possible scores from 15 (no GSA) to 90 (severe GSA). Lower scores are associated with higher GSA. Group mean scores will be summarized.

Resilience will be determined based on the 14-item Resilience Scale for Inflammatory Bowel Disease (RISE IBD) scale. RISE-IBD consists of 14 statements governing four domains scored on a scale ranging from 0-4. Positively worded statements in the survey (Statements 1-2, 4-5, 7, 9-13) are scored from 0 (Not True) to 4 (Always True) and negatively worded statements in the survey (Statements 3, 6, 8 and 14) are reverse scored from 0 (Always True) to 4 (Not True) for a possible overall scoring range of 0-56. Higher scores reflect greater patient resilience. Group mean scores will be summarized.

The Patient-Reported Outcomes Measurement Information System (PROMIS)-29 questionnaire will be used to assess Health-related Quality of Life. PROMIS-29 consists of 29 questions/statements which include 4 items across 7 domains along with a single Pain Intensity item. Pain Intensity is measured on a scale from 0 (No Pain) to 10 (Worst pain imaginable). Responses to the other 28 items are scored from 1-5. Raw scores are converted to a T-score that centers at mean T-score of 50 with a Standard Deviation of 10 in a general, reference population. Higher scores indicate higher degree of the measured trait. Group mean scores will be summarized.

For patients with CD, IBD activity will be assessed using the Short Crohn's Disease Activity Index (CDAI). The CDAI consists of 3 questions assessing CD symptoms/activity daily over the prior 7 days. The three questions relate to the number of liquid or soft stools each day; abdominal pain severity each day; and general well-being each day. Scoring is summarized as follows:

44 + (2 x the number of liquid or soft stools each day for 7 days) + 5 x the sum of seven daily abdominal pain ratings (0 = none, 1 = mild, 2 = moderate, 3 = severe)] + 7 x the sum of seven general well-being ratings (0 = generally well, 1 = slightly under par, 2 = poor, 3 = very poor, 4 = terrible)]

Overall CDAI scores range from 0 to approximately 600. Higher scores are associated with increased Crohn's disease severity. Group mean scores will be summarized.

For patients with UC, IBD activity will be assessed using Simple Clinical Colitis Activity index (SCCAI). The SCCAI consists of 6 questions assessing UC disease symptoms. Three questions: Bowel Frequency (per day), Urgency of Defecation, and Blood in Stool are scored on a 0-3 scale with higher scores indicating increasing severity). Bowel Frequency (per night) is scored from 0-2 with higher scores denoting greater frequency and General well-being is scored from 0-4 with higher scores indicative of decreasing well being. A final question assigns a point per extracolonic manifestation for any of the following features (uveitis, pyoderma gangrenosum, erythema nodosum, or arthropathy). Overall SCCAI range is 0-19 with higher overall scores being associated with increased severity of UC symptoms. Group mean scores will be summarized.